26.73

1.00% -0.27

Pre-market: 27.00 0.27 +1.01%

Arrivent Biopharma Inc (AVBP)

Overview News Price History Discussions Forecast

Arrivent Biopharma Inc stock is traded at $26.73, with a volume of 433.36K. It is down -1.00% in the last 24 hours and down -13.48% over the past month. ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. The company focuses on advancing its lead product candidate, firmonertinib, for the treatment of epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC), and developing a pipeline of novel therapeutics, including next-generation antibody-drug conjugates such as ARR-217 (MRG007), with an initial focus on solid tumors.

Previous Close:

$27.00

Open:

$27.1

24h Volume:

433.36K

Relative Volume:

0.90

Market Cap:

$1.24B

Revenue:

Net Income/Loss:

$-166.31M

P/E Ratio:

-5.993

EPS:

-4.4602

Net Cash Flow:

$-160.59M

1W Performance:

-4.09%

1M Performance:

-13.48%

6M Performance:

+31.35%

1Y Performance:

+29.57%

1-Day Range:

$26.43

$27.68

1-Week Range:

$25.91

$28.20

52-Week Range:

$16.10

$32.14

Arrivent Biopharma Inc Stock (AVBP) Company Profile

Name

Arrivent Biopharma Inc

Sector

Healthcare (1106)

Industry

Biotechnology (618)

Phone

240-780-6356

Address

18 CAMPUS BLVD., NEWTOWN SQUARE

Employee

Twitter

Next Earnings Date

2026-05-11

Latest SEC Filings

AVBP's Discussions on Twitter

Compare AVBP vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AVBP Arrivent Biopharma Inc	26.73	1.26B	0	-166.31M	-160.59M	-4.4602
VRTX Vertex Pharmaceuticals Inc	434.52	110.03B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	638.88	67.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	806.46	50.76B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	297.45	40.12B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	151.56	32.68B	742.00K	-1.37B	-1.07B	-7.0731

Arrivent Biopharma Inc Stock (AVBP) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-12-26	Resumed	BTIG Research	Buy
Dec-10-25	Initiated	BTIG Research	Buy
Nov-25-25	Initiated	Truist	Buy
Jul-10-25	Resumed	Goldman	Buy
Mar-20-25	Initiated	B. Riley Securities	Buy
Mar-10-25	Initiated	Guggenheim	Buy
Jul-22-24	Initiated	Oppenheimer	Outperform
Apr-30-24	Initiated	H.C. Wainwright	Buy
Feb-20-24	Initiated	Citigroup	Buy
Feb-20-24	Initiated	Goldman	Buy
Feb-20-24	Initiated	Jefferies	Buy

View All

Arrivent Biopharma Inc Stock (AVBP) Latest News

May 22, 2026

ArriVent BioPharma Shares Edge Lower Amid Sector CautionKAMA Signal - Newser

May 22, 2026

Cantor Fitzgerald reiterates Overweight rating on ArriVent stock By Investing.com - Investing.com Canada

May 22, 2026

May 17, 2026

(AVBP) Movement as an Input in Quant Signal Sets - Stock Traders Daily

May 17, 2026

Wall Street analysts think ArriVent BioPharma, Inc. (AVBP) could surge 72.44%: Read this before placing a bet - MSN

May 17, 2026

LifeSci Capital Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $42 - Moomoo

May 17, 2026

May 16, 2026

ArriVent delays Phase 3 trial to mid-2026 but extends cash runway to Q4 2027, reducing funding risk. - Pluang

May 16, 2026

ArriVent BioPharma: Stronger Balance Sheet And Pipeline Upside Reinforce Our Bull Case - Seeking Alpha

May 16, 2026

May 13, 2026

Citi Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Cuts Target Price to $43 - Moomoo

May 13, 2026

Oppenheimer Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $50 - Moomoo

May 13, 2026

A Quick Look at Today's Ratings for ArriVent BioPharma(AVBP.US), With a Forecast Between $42 to $50 - Moomoo

May 13, 2026